Aleglitazar

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aleglitazar
Aleglitazar.svg
Names
IUPAC name
(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid
Other names
Ro-0728804, R-1439
Identifiers
475479-34-6 N
ChEMBL ChEMBL519504 YesY
ChemSpider 8450255 YesY
DrugBank DB08483 YesY
7405
Jmol 3D model Interactive image
Interactive image
KEGG D08845 YesY
PubChem 10274777
UNII 41T4OAG59U YesY
Properties
C24H23NO5S
Molar mass 437.51 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]

References[edit]

  1. ^ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17. 
  2. ^ "Roche halts diabetes drug trial in blow to pipeline". Roche. Retrieved 2013-07-10.